LDS/Medical Tests/Bladder Tumor Antigen (BTA)

Bladder Tumor Antigen (BTA)

Bladder tumor antigen (BTA) is an immunoassay that is utilized for the qualitative or quantitative analysis and detection of bladder cancer antigen in urine. The detection of this antigen (tumor marker) is extremely useful in the detection and monitoring of cancer treatment and recurrence of bladder carcinoma. This test is not 100% specific and false positive results have been reported in association with diseases that “leak” human complement factor H (hcfH) (see Interpretation). It should be used only in patients with tissue biopsy diagnosed urothelial (transitional cell) carcinoma. The sensitivity of the test increases with increasing histologic grade (degree of aggressiveness) of the cancer. Overall, the test is more sensitive than voided urine cytology, with the exception of in situ disease. In patients with a confirmed history of bladder cancer with no current evidence of tumor, this test was much less specific than voided urine cytology. When an individual has been diagnosed with bladder carcinoma they are typically followed to monitor recurrence by use of urine cytology and cystoscopy. Cystoscopy is invasive, painful, and a more expensive way to monitor, and cytology is relatively insensitive, hence the approval of BTA immunoassay testing will be beneficial to patients. Bladder cancer is the fourth most common cancer in men and the ninth most common form of cancer in women in the United States. Individuals who have had a diagnosis of urothelial (transitional cell) carcinoma in the past are 75% more likely to have a recurrence, so constant monitoring is essential.

  • May be helpful in the initial diagnosis of bladder carcinoma (cancer)
  • Follow-up treatment for bladder cancer
  • Monitoring the progress of bladder cancer treatment
  • Monitoring for recurrence of bladder cancer

Increased in:

  • Individuals with urothelial bladder cancer
  • Recurrent bladder cancer

The test is not 100% specific. Positive results have been obtained in patients with urinary tract infection, certain STDs, cystitis, kidney stones, hematuria, and recent procedures or trauma of the bladder. In addition, transitional cell carcinoma arising in the ureter or kidney could yield a positive result.

Negative (Bladder tumor associated antigen not detected).

 

 

Qualitative Immunoassay

Urine (minimum 2mL) collected in sterile urine cup

Stability

  • Ambient: 2 days
  • Refrigerated: 14 days
  • Frozen: up to 6 months

Plasma, serum, whole blood and bladder washings are unacceptable specimen types.

Urinalysis and urine cytology, cystoscopic examination,PSA (total), Nuclear Matrix Proteins (NMP22), UroVysion™ FISH, Ki-67 and p53 Tissue Assay, p21 (Waf1/Cip 1), p16, Cytokeratin 5,6 (CK 5,6) by Immunohistochemistry.
1-5 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login